NCT02521753

Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients

Effect Polyunsaturated Fatty Acids or Magnesium in Metabolic, Hormonal, and Inflammatory Profile in Obese Women With Polycystic Ovary Syndrome. A Randomized Clinical Trial

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 123 (actual)
• Sponsor: Coordinación de Investigación en Salud, Mexico · Other Government
• Sex: Female
• Age: 18 Years – 38 Years
• Healthy volunteers: Not accepted

Summary

Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in reproductive age women. PCOS is usually characterized by an excessive androgen production, menstrual irregularities, and polycystic ovaries. Women with PCOS are often obese and have a varying degree of insulin resistance (IR). Weight reduction constitutes the initial treatment for these patients. Metformin has proven to be useful in IR and is frequently used in PCOS. However metformin use may be accompanied by gastrointestinal discomfort, and a high abandon rate. Other therapeutic alternatives such as magnesium and polyunsaturated fatty acids have been used in other IR states and may be useful in PCOS. The aim of this study is to asses the efficacy of these alternatives in obese PCOS patients.

Detailed description

Polycystic Ovary Syndrome (PCOS)

Conditions

• Polycystic Ovary Syndrome
• Obesity

Interventions

Type	Name	Description
DRUG	Metformin	Intervention also includes weight reduction diet and exercise therapy
DIETARY_SUPPLEMENT	Magnesium	Intervention also includes weight reduction diet and exercise therapy
DIETARY_SUPPLEMENT	PUFA	Intervention also includes weight reduction diet and exercise therapy

Timeline

• Start date: 2015-08-01
• Primary completion: 2020-08-01
• Completion: 2025-03-01
• First posted: 2015-08-13
• Last updated: 2025-04-01

Locations

1 site across 1 country: Mexico